BioCentury | Feb 2, 2009
Clinical News

Pagoclone: Phase IIb start

...2008). Indevus Pharmaceuticals Inc. (NASDAQ:IDEV), Lexington, Mass. Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), Jerusalem, Israel Product: Pagoclone...
BioCentury | Oct 6, 2008
Analyst Picks & Changes

Analyst picks & changes

...raised her target to $5 from $3. She said a deal with Teva (NASDAQ:TEVA) for pagoclone...
BioCentury | Sep 29, 2008
Finance

Ebb & Flow

...depot to treat male hypogonadism. Separately, Indevus granted Teva (NASDAQ:TEVA) an exclusive worldwide license to pagoclone...
BioCentury | Sep 29, 2008
Company News

Indevus, Teva deal

...Indevus granted Teva an exclusive, worldwide license to pagoclone . The cyclopyrrolone GABA receptor agonist is...
...will reimburse Indevus for the Phase IIb trial and conduct the Phase III program for pagoclone...
BioCentury | Sep 27, 2008
Company News

Indevus up on Nebido plans

...of Bayer (Xetra:BAY). On Friday, Indevus also granted Teva (NASDAQ:TEVA) an exclusive, worldwide license to pagoclone...
BioCentury | Sep 27, 2008
Company News

Teva licenses pagoclone from Indevus

...Indevus (NASDAQ:IDEV) granted Teva (NASDAQ:TEVA) an exclusive, worldwide license to pagoclone . The cyclopyrrolone GABA receptor...
BioCentury | Jun 18, 2007
Clinical News

Pagoclone: Interim Phase II data

...U.S. Phase II EXPRESS trial. After 3 months, patients who received placebo in EXPRESS and pagoclone...
...trial) in the percentage of syllables stuttered, vs. a 40% reduction for patients who received pagoclone...
...and the extension. Also, 80% of former placebo patients and 90% of patients who received pagoclone...
BioCentury | Oct 2, 2006
Finance

3Q setbacks

...the Phase III ASSERT trial to treat sickle cell anemia Indevus (IDEV) Discontinues development of pagoclone...
BioCentury | Oct 2, 2006
Finance

Ebb & Flow

...B20). Indevus (IDEV) slipped $0.03 to $5.92 on the week after it discontinued development of pagoclone...
BioCentury | Oct 2, 2006
Clinical News

Pagoclone: Development discontinued

...IDEV discontinued development of pagoclone in PE after an interim analysis of an 8-week, double-blind, U.S...
...in the highest dose (0.6 mg) vs. placebo. Indevus Pharmaceuticals Inc. (IDEV), Lexington, Mass. Product: Pagoclone...
Items per page:
1 - 10 of 50